+

WO1999003979A1 - Methodes de preparation d'un tissu cellulaire artificiel - Google Patents

Methodes de preparation d'un tissu cellulaire artificiel Download PDF

Info

Publication number
WO1999003979A1
WO1999003979A1 PCT/GB1998/002147 GB9802147W WO9903979A1 WO 1999003979 A1 WO1999003979 A1 WO 1999003979A1 GB 9802147 W GB9802147 W GB 9802147W WO 9903979 A1 WO9903979 A1 WO 9903979A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
cells
selective
tissue
scaffold
Prior art date
Application number
PCT/GB1998/002147
Other languages
English (en)
Inventor
Richard Wolowacz
Sorrel Wolowacz
Julie Marie Sheridan
Original Assignee
Smith & Nephew Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith & Nephew Plc filed Critical Smith & Nephew Plc
Priority to AU84514/98A priority Critical patent/AU8451498A/en
Publication of WO1999003979A1 publication Critical patent/WO1999003979A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Definitions

  • the present invention relates to the field of cell culturing and in particular relates to improved methods for culturing cells in vitro to form a tissue equivalent (i.e. tissue engineering) for the treatment of tissue defects in mammalian patients.
  • tissue equivalent i.e. tissue engineering
  • tissue defects such as skin ulceration in various forms e.g. pressure sores and venous ulcers, serious burns and other tissue defects such as articular and meniscal cartilage defects, snapped ligaments, tendons and the like has in recent times being directed towards the production, in vitro, of a tissue equivalent which is then grafted onto the defect site to replace or augment the damaged tissue.
  • this in vitro production involves first obtaining a sample of autologous or allogeneic cells. Where autologous cells are utilised these are generally harvested from an unaffected site on the patient. Where allogenic cells are utilised these may be obtained from a variety of different sources such as tissue banks. Cells extracted from the sample are usually cultured in an aqueous medium where they proliferate and are culture-expanded by passage. The media is usually supplemented with an animal serum to provide some of the necessary constituents for optimal cell growth and proliferation.
  • the cells from the culture expansion are then usually seeded onto a supporting structure such as a bioresorbable three dimensional matrix or seeded into a supporting structure such as collagen gel to form a seeded construct and then, in the presence of an aqueous serum-containing media, the construct is incubated for a sufficient period of time to form either an equivalent to the tissue to be replaced or is developed in vitro to the point where it is capable of being grafted to the defect site and develop further into such a tissue equivalent.
  • a supporting structure such as a bioresorbable three dimensional matrix or seeded into a supporting structure such as collagen gel
  • ECM extracellular matrix
  • a major constituent of the ECM are collagens, a family of highly characteristic fibrous proteins. Collagen is present in a variety of known types with particular tissues displaying a predominance of a particular form. For example, cartilage is associated with collagen II and collagen IX. Skin and tendon is associated with collagen I and III. Bone and meniscus cartilage is associated with collagen I.
  • Other constituents of the ECM include glycosaminoglycans, fibronectin, vitronectin and other growth factor binding proteins e.g.
  • LTBP latent transforming growth factor binding proteins 1,2,3.
  • the constituents of the ECM are secreted locally by cells in the ECM. In most connective tissues these constituents are secreted largely by fibroblasts. In some specialised connective tissues, such as cartilage and bone, they are secreted by cells such as chrondrocytes and osteoblasts respectively.
  • the present invention is based, in part, on the premise that certain proteins present particularly in serum containing media commonly used in cell culturing and commercially available as such may in fact have an inhibitory effect on the formation of ECM components during the in vitro production of tissue equivalents. That is, the presence of enzymes especially of the gelatinolytic type which are present in the serum degrade some of the collagen and other ECM components produced by the culturing cells. As a result, the formation of an ECM is prolonged and consequentially so is the formation of an engraftable tissue equivalent.
  • a method for the in vitro production of a tissue equivalent comprising mammalian cells supported by a scaffold, which method comprises the step of containing said cells supported by a scaffold in the presence of an effective amount of a matrix metalloproteinase inhibitor.
  • tissue culture media comprising an effective amount of a matrix metalloproteinase inhibitor.
  • tissue culture media comprising an effective amount of a matrix metalloproteinase inhibitor.
  • a method for the treatment of tissue defects on a mammalian patient comprising the step of applying to said patient a tissue equivalent as provided hereinbefore.
  • a method for reducing matrix metalloproteinase activity in tissue culture media comprising the step of admixing said tissue culture media with an effective amount of a matrix metalloproteinase inhibitor.
  • a method for increasing the rate of collagen deposition during the in vitro production of a tissue equivalent comprising mammalian cells supported by a scaffold
  • said method comprises the step of containing said cells supported by a scaffold in the presence of an effective amount of a matrix metalloproteinase inhibitor.
  • matrix metalloproteinase inhibitor is intended to mean an inhibitor i.e. a substance that is capable of restricting, hindering or preventing the activity of a matrix metalloproteinase (MMP).
  • MMP matrix metalloproteinase
  • the amount of collagen deposition during the production of a tissue equivalent is the equilibrated result of collagen production by the culturing cells and the rate of collagen degradation mainly by MMP's present in the serum containing tissue culture media.
  • the present invention pushes this equilibration in favour of overall collagen deposition by inhibiting collagen degradation as a result of serum MMP activity.
  • Matrix metalloproteinases are naturally occurring proteases present in the mammalian body which are believed to be involved in a number of biological processes which include remodelling of extracellular matrix components, angiogenesis and metastatic invasion of tumour cells.
  • a number of MMPs have now been identified although this may not necessarily be exhaustive of all MMPs present in the mammalian body. Nagase et al : (1992) Matrix, supplement No 1 , pp421-424, incorporated herein by reference, proposed a number of criteria for classifying a new proteinase as an MMP.
  • a proteinase whose activity is blocked by 1,10 phenanthroline which exists in a latent form activated by organomercurial compounds; which is inhibited by tissue inhibitor of matrix metalloproteinase (TIMP), which hydrolyses at least one ECM component; requires calcium for activity/stability; a proteinase which has zinc as an intrinsic metal ion.
  • TRIP matrix metalloproteinase
  • MMP1 MMP1
  • MMPs may be conveniently divided into four classes, collagenases, gelatinases, stromelysins and more recently membrane type MMP (MT-MMP). Within each class, there are individual MMP types (herein called 'members'). A particular class of MMP or even a particular MMP member may be specifically inhibited in the presence of an MMP inhibitor although frequently an inhibitor is not specific for a particular class or member but rather displays selectivity towards inhibiting a particular class or member.
  • Collagenases are a class of MMP believed to be primarily responsible for the in vivo cleavage of native triple helical fibril collagen.
  • Collagenase inhibitors may be either synthetic or natural.
  • Natural collagenase inhibitors include tissue inhibitors of matrix metalloproteinase (TIMPs) 1 ,2,3 and 4.
  • collagenase inhibitors include inhibitors based on hydroxamic acid, see WO 90/05716, WO90/05719 and WO92/13831, all of which are incorporated herein by reference.
  • Other zinc binding inhibitors include derivatives of formylhydroxylamine, sulphydryl, phosphinate and carboxylates.
  • hydroxamic acid inhibitor is known by the trade name GALARDIN, a synthesis for which is disclosed in US 5189178 and US 5114953, both of which are incorporated herein by reference.
  • GALARDIN a synthesis for which is disclosed in US 5189178 and US 5114953, both of which are incorporated herein by reference.
  • collagenase inhibitors see also EP-A-126,974, EP-159396, US 4599361 and US 4743587, all of which are incorporated herein by reference.
  • Further examples of collagenase inhibitors include collagenase antibodies, either polyclonal or monoclonal and includes the Fab fragments thereof.
  • Other examples of collagenase inhibitors include EDTA, cysteine and tetracyclines.
  • the class of stromelysins includes at least the members MMP 3 and 6. These MMPs have a wide range of ECM substrate specificity which includes laminin and glycosaminoglycans (GAGs). Examples of known stromelysin inhibitors include substances currently under development for the treatment of cancer and known by the designations, CDP-845 (Celltech), CH715 (Chiroscience), GALARDIN (Ligand pharmaceutical) and L-758354 (Merck). Polyclonal or monoclonal antibodies including Fab fragments to the stromelysin class or members thereof may also be utilised.
  • Gelatinases display a substrate specificity towards basement collagen and denatured fibrillar collagen.
  • known gelatinase inhibitors include the tetracyclines, chemically modified tetracyclines (CMTs), CDP-845, CH-715, CT-1746 and Rega 3G12.
  • CMTs chemically modified tetracyclines
  • Useful CMTs include doxycycline and minocycline and preferred CMTs include CMT 2,3,7,8.
  • CMT 6 may also be used but is less favoured due to poor solubility in aqueous media in the absence of a further solvent e.g. Dimethyl sulfoxide (DMSO). It is understood that antibodies and fragments thereof to the gelatinase class or members thereof may be utilised.
  • DMSO Dimethyl sulfoxide
  • the inhibitor of the present invention may be irreversible, or reversible in which case they may be of the competitive, non- competitive, uncompetitive or mixed type.
  • the type of inhibition displayed can be determined enzymologically according to standard textbook protocol. See, for example, Cornish-Bowden ; Fundamentals of enzyme kinetics; Butterworths, London.
  • the inhibitor is preferably water soluble and furthermore does not adversely effect cell viability or phenotype expression.
  • the inhibitor such as those illustrated above may be selective for a particular class of MMP or even a particular member. Inhibitors selective for the gelatinase class or particular members thereof are preferred selective inhibitors although MMP inhibitors that are non-selective i.e.
  • non- selective MMP inhibitors include the tetracyclines and the CMTs 1 ,2,3,6,7 and 8 (available from CollaGenex, Newtown, PA USA).
  • Particularly preferred non-selective tetracycline MMP inhibitors include doxycycline and the specific compound tetracycline, oxytetracycline and sancycline (available from Sigma Co.)
  • an effective amount of the inhibitor should be used.
  • effective amount we mean an amount of inhibitor sufficient to produce a detectable reduction in MMP activity in serum-containing tissue culture media when compared with appropriate control e.g. in tissue culture media that has not been supplemented with a MMP inhibitor.
  • MMP activity in the tissue culture media of the present invention may be measured by fluorescence substrate analysis, see Knight CG et al (1992); Biochem J; 260, p259-263, incorporated herein by reference.
  • Model substrates for collagenase, gelatinase and stromelysin classes which may be measured by fluorescence include fluorescence groups 7-methoxycoumarin and N- methylanthranilic acid attached to a short peptide.
  • the tissue culture media of the present invention may be prepared from commercially available basal media supplemented with animal serum, antibiotics such as penicillin and streptomycin, glutamine, buffers such as Hepes, non-essential amino acids, other factors and further supplemented with the inhibitor.
  • Suitable basal media includes Ames medium, Dulbeco's modified Eagles medium (DMEM), Basal medium Eagle (BME), BGJB medium, Roswell Park Memorial Institute media (RPMI), Click's medium, CRCM-30 medium, CMRL-1066 medium, Minimally Essential medium (MEM), (available from Sigma Biosciences).
  • Animal serum typically utilised in current cell culturing techniques include bovine, ovine, equine, human, chicken, goat, porcine and rabbit derived serum.
  • Animal serum may be derived from fetal or neo-natal animals. Commonly, serum is derived from foetal animals.
  • the serum of the present invention is ovine or bovine.
  • a common and popular animal serum in current cell culturing techniques is foetal calf serum.
  • the animal serum utilised in the present invention is foetal calf serum at a concentration of between 5 to 60% v/v, more preferably 10% to 20% v/v.
  • the present invention may also find utility with serum-free media (so-called 'defined media') since mammalian cells themselves secrete a basal level of MMP during normal cellular activity.
  • the inhibitor may be admixed with the media prior to cell culturing although it may be added at any appropriate time during the culturing process. Indeed it may be desirable to admix after the culturing process has begun and in particular after the cells have been allowed to proliferate for several days.
  • Cells used in the present invention are typically mammalian autologous or allogeneic cells. Xenogeneic cells may be used but are currently unfavourable due to immunological problems with their use.
  • the present invention is useful for any cell culturing process where the formation of an ECM is required but is particularly suited to the production of a tissue equivalent.
  • Autologous cells may be obtained by biopsy from the patient and treated with degradative enzymes e.g. trypsin and collagenases to separate the cells for use in the culturing process. Allogenic cells may be obtained from a number of sources such as tissue banks.
  • the cells used in the present invention may be terminally differentiated or capable of undergoing phenotypic change e.g. stem cells, committed cells, pluripotent stem cells and other progenitor cells. It is understood that this includes the processes of differentiation, de-differentiation and trans-differentiation.
  • Cells useful therefore include mesenchymal derived cells, epithelial and endothelial cells.
  • Cells useful in the present invention include fibroblasts, keratinocytes, chrondrocytes, tenocytes, ligamentocytes, fibrochrondrocyt.es, bone marrow stromal cells and other mesenchymal stem cells e.g. dermal papillae cells.
  • Other cells include melanocytes, hepatocytes, pancreatic and urothelial cells.
  • the invention is particularly useful in the production of loose, dense, cartilagenous and mineralized connective tissue equivalents. Suitable examples thereof include skin, meniscus and articular cartilage, tendons, ligament and bone.
  • tissue equivalent we mean an in vitro produced structure comprising cells supported by an artificial scaffold, whereby said structure emulates the structural and functional characteristics of a particular tissue either when grafted to or following grafting to a target site on a patient.
  • tissue equivalents such as DERMAGRAFT (Trademark) and APPLIGRAFTM.
  • the present invention is further useful in the production of cell seeded wound dressings, see for example, our patent applications WO 91/13638 and WO 97/06835 both of which are inco ⁇ orated herein by reference.
  • tissue equivalents are disclosed in, for example, US 5,460,939, WO90/02796, WO 90/12603, US 5,256,418, WO96/13974, all of which are incorporated herein by reference.
  • Suitable scaffold materials are preferably biodegradable and are not inhibitory to cell growth or proliferation.
  • the materials should not elicit an adverse reaction from the patients body and should be capable of sterilisation by e.g. ethylene oxide treatment (allowing sufficient time for degassing), prior to seeding with cells .
  • Suitable materials therefore include biodegradable polyesters such as polylactic acid (PLA), polygiycolic acid (PGA), polydioxanone, polyhydroxyalkanoates e.g. polyhydroxybutyrate (ICI) and hyaluronic acid derivatives e.g. HYAFF (Fidia).
  • suitable materials include those disclosed in our patent applications WO 91/13638 and WO 97/06835, inco ⁇ orated herein by reference such as hydrophilic polyurethanes, polyetherpolyester, polyethylene oxide, polyetherpolyamide, carboxymethylcellulose, ethylene-vinyl acetate copolymers, polybutadienes, styrene-butadiene-styrene block copolymers and the like.
  • scaffold materials are collagen based e.g. cross-linked collagen/elastin material, cross-linked collagens manufactured from acid-soluble type I bovine collagen sources, collagen gels, COLLASTAT (trade name, Vitaphore), COLETICA (trade name). Collagen from natural or recombinant sources may be used.
  • the scaffold of the present invention may be in the form of a three dimensional matrix or a layer, for example a continuous film or gel.
  • the matrix structure may be manufactured from fibres of a suitable material which is then textile processed (e.g. braided, knitted, woven or non-woven, melt-blown, felted and hydroentangled) and further manipulated into a desired three dimensional shape e.g. ligament or tendon following which the matrix is seeded with cells which are optionally predispersed in collagen or fibrin gel.
  • the matrix structure may also assume other forms e.g. sponges or foams.
  • the in vitro process generally comprises submerging the cells or structure comprising cells supported by a scaffold, in the tissue curture medium of the present invention contained within a cell culture vessel such as a cell culture flask, said flask formed from suitable materials such as high impact polystyrene and which is preferably transparent to allow viewing of the culturing process.
  • a cell culture vessel such as a cell culture flask
  • suitable materials such as high impact polystyrene and which is preferably transparent to allow viewing of the culturing process.
  • the cell culture is then incubated at physiologically acceptable conditions over several days until the desired state is achieved.
  • a proportion of the tissue culture medium of the present invention is replaced with fresh medium (so called 'split feeding').
  • tissue culture media comprising an artificial i.e. supplemented matrix metalloproteinase inhibitor.
  • extracted animal serum in a form suitable for cell culturing techniques comprising an artificial matrix metalloproteinase inhibitor.
  • a method of producing a tissue equivalent comprising cells supported by a scaffold, said method comprising the step of containing said cells supported by a scaffold in tissue culture media comprising animal serum, which media is supplemented with a matrix metalloproteinase inhibitor.
  • tissue scaffold for cell seeding Braided polyester three dimensional tubular scaffolds ( approx. 40mm length by 3mm) were soaked in 70% v/v alcohol in water for 1.5 hours and left to soak for 24 hours in antibiotic/antimycotic solution at 4°c.
  • the scaffolds were removed from antibiotic wash and rinsed in sterile distilled water, sterile phosphate buffered solution (PBS) and in tissue culture medium (TCM) comprising 10% fetal calf serum (consisting of : DMEM (with sodium pyruvate, 1000mg/L glucose, pyridoxine) 85% v/v, Gibco Ltd), 10% v/v heat inactivated foetal calf serum (Gibco Ltd), 0.02% v/v Hepes buffer (1 M, Gibco Ltd), 0.01 % v/v non essential amino acids; 0.01 % v/v/v penicillin/streptomycin (5000IU/ml - 5000 ⁇ g/ml) and 0.01% v/v L- glutamine). Scaffolds were placed in fresh TCM and incubated at 37°c.
  • PBS sterile phosphate buffered solution
  • TCM tissue culture medium
  • Seeded scaffolds were then removed from the shaker and placed three seeded scaffolds (herein 'devices') per culture flask into culture flasks (Falcon T25 flasks, Becton Dickinson) containing TCM (10ml). The flasks were then transferred to CO 2 incubators and incubated at 37°c.
  • one third of the remaining cultures were supplemented with 20 ⁇ g/ml doxycycline (CollaGenex, Inc., Newtown, PA, USA) ( and were designated group 2), one third with 40 ⁇ g/ml doxycycline (group 3), with the remaining third containing no doxycycline (group 1). Cultures were then incubated for 12 days, split feeding on alternate days, supplementing with fresh doxycycline where applicable.
  • Table 1 Total average collagen (hydroxyproline assay) per device according to example 1 (four weeks*.
  • Ovine articular chrondrocytes were isolated from 8 week old lambs by digestion in 0.2% collagenase at 37°c. The isolated cells were seeded onto PGA felts and cultured in DMEM supplemented with FCS (10%) in Apollo bioreactors (ATS, La Jolla, CA) at a seed level of 4 x 10 6 cells per bioreactor either without supplemented doxycycline (control, group 1) or with supplemented doxycycline (40 ⁇ g/ml, group 3). Collagen levels measured after four weeks are represented in table 3 below.
  • Table 3 Total average collagen (hydroxyproline assays per device according to example 3
  • example 1 The method of example 1 was repeated using PLA yarns, Huff fibroblasts and the following inhibitors: GALARDIN (10 nmolar, 100 nmolar) Peptide hydroxymate N-1405 (Bachem, 10 ⁇ molar and
  • TIMP 1,2,3 and 4 (10- 11 molar, Celltech).
  • keratinocytes Human SCABER cells, American Type culture collection , Maryland, USA.
  • Example 8 The method of example 4 and 5 was repeated using tenocytes
  • Example 9 The method of example 4 and 5 was repeated using human mesenchymal stem cells derived from bone marrow.
  • the method of claim 4 and 5 was repeated using endothelial cells derived from human umbilical sources.
  • Xcell II zymography system Novex was assembled according to the manufacturer's instructions with 2 Novex precast gelatin gels. Test sera samples were activated using aminophenylmercuric acetate (APMA, 10%). As a control, sera samples were not activated with APMA. Sample buffer (Tris-HCL (0.5M, 400 ⁇ l, pH 6.8), Sucrose (60%, 2.5ml), SDS (20%w/v, 1.75ml), H 2 O (350 ⁇ l), Bromophenol Blue, (1mg) was mixed 1:1 with the sample sera ( obtained from Gibco) below and loaded onto both gels.
  • Tris-HCL 0.5M, 400 ⁇ l, pH 6.8
  • Sucrose 60%, 2.5ml
  • SDS 20%, 2.5ml
  • SDS 20%w/v, 1.75ml
  • H 2 O 350 ⁇ l
  • Bromophenol Blue (1mg) was mixed 1:1 with the sample sera ( obtained from Gibco) below and loaded onto both gels.
  • Recombinant MMP2 and 9 were obtained from Chemicon.
  • the gels were allowed to run at 125v, 40mA for 90 minutes, following which the gels were disassembled and placed in renaturing buffer according to manufacturers instructions for 30 minutes. The gels were then transferred into developing buffer for overnight incubation at 37°c. The gels were then removed from the incubator and placed into 10% methanol, 10% acetic acid (destain solution) for 20 minutes agitation. The gels were then transferred into Coomassia Blue-R-250 stain for 20 minutes agitation and then back into destain for 15 minutes. The destain solution was changed and then agitated for 20 minutes before being changed again for a final 30 minutes agitation. The results are displayed in fig.1.
  • Well 6 illustrates MMP 9 control used as a marker. Two bands are evident, one being the active form of MMP 9 and one being the proform.
  • Well 5 illustrates MMP2 band as a marker.
  • Well 1 displays prominent bands corresponding to the active and proform of MMP9 with lighter but evident MMP 2 activity.
  • Well 2 displays prominent levels of MMP 9 proform and lighter but still evident proform MMP 2 activity.
  • Wells 3 and 4 displays evident MMP 9 activity which is less than that observed with wells 2 and 3. Light but evident bands of MMP 2 pro and active forms were present in wells 3 and 4. These results indicate the present of MMP activity in commercially available animal sera.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne l'utilisation d'inhibiteurs des métalloprotéinases matricielles (MMP), tels que la collagénase, la stromélysine et la gélatinase, dans la production d'équivalents tissulaires. Les inhibiteurs sont particulièrement utilisés pour inhiber les MMP présentes dans le sérum animal utilisé dans la technique de production, améliorant ainsi le dépôt de collagène. Le milieu de culture tissulaire et le sérum animal extrait comprenant un inhibiteur complémentaire de MMP .
PCT/GB1998/002147 1997-07-17 1998-07-17 Methodes de preparation d'un tissu cellulaire artificiel WO1999003979A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU84514/98A AU8451498A (en) 1997-07-17 1998-07-17 Methods for the preparation of artificial cellular tissue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9714936.3 1997-07-17
GBGB9714936.3A GB9714936D0 (en) 1997-07-17 1997-07-17 Cell culture products

Publications (1)

Publication Number Publication Date
WO1999003979A1 true WO1999003979A1 (fr) 1999-01-28

Family

ID=10815918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/002147 WO1999003979A1 (fr) 1997-07-17 1998-07-17 Methodes de preparation d'un tissu cellulaire artificiel

Country Status (3)

Country Link
AU (1) AU8451498A (fr)
GB (1) GB9714936D0 (fr)
WO (1) WO1999003979A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048617A2 (fr) * 1999-02-18 2000-08-24 Renovo Limited Ramollissement des tissus conjonctifs
WO2001072347A1 (fr) * 2000-03-27 2001-10-04 Shiseido Company, Ltd. Agents favorisant la formation d'une membrane de base de la peau, agents favorisant la formation d'une peau artificielle et procede de production de peau artificielle
WO2002049593A2 (fr) * 2000-12-20 2002-06-27 Henkel Kommanditgesellschaft Auf Aktien Utilisation d'enzymes de reparation de l'adn en tant qu'inhibiteurs de mmp-1
US7160333B2 (en) 2000-08-04 2007-01-09 Depuy Orthopaedics, Inc. Reinforced small intestinal submucosa
US7163563B2 (en) 2001-07-16 2007-01-16 Depuy Products, Inc. Unitary surgical device and method
US7201917B2 (en) 2001-07-16 2007-04-10 Depuy Products, Inc. Porous delivery scaffold and method
US7354627B2 (en) 2004-12-22 2008-04-08 Depuy Products, Inc. Method for organizing the assembly of collagen fibers and compositions formed therefrom
US7361195B2 (en) 2001-07-16 2008-04-22 Depuy Products, Inc. Cartilage repair apparatus and method
US7569233B2 (en) 2004-05-04 2009-08-04 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
US7595062B2 (en) 2005-07-28 2009-09-29 Depuy Products, Inc. Joint resurfacing orthopaedic implant and associated method
US7927606B2 (en) 2003-02-06 2011-04-19 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
EP2543396A1 (fr) * 2010-03-04 2013-01-09 Shiseido Company, Ltd. Peau artificielle
US8864844B2 (en) 2004-05-11 2014-10-21 Synthasome, Inc. Tissue scaffold
JP2015533505A (ja) * 2012-10-18 2015-11-26 ライフライン サイエンティフィック インコーポレイテッドＬｉｆｅｌｉｎｅ Ｓｃｉｅｎｔｉｆｉｃ， Ｉｎｃ． 生物材料特性の維持および保存方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003785A1 (fr) * 1986-11-20 1988-06-02 Vacanti Joseph P Neomorphogenese chimerique d'organes par implantation cellulaire controlee mettant en oeuvre des matrices artificielles
EP0282746A1 (fr) * 1987-02-19 1988-09-21 Takeda Chemical Industries, Ltd. Procédé de préparation de tissu cultivé de manière artificielle
EP0435362A1 (fr) * 1989-12-04 1991-07-03 The Research Foundation Of State University Of New York Composition contenant un agent non-stéroide anti-inflammatoire et une tétracycline à effet nonantibactérien
EP0550760A1 (fr) * 1991-07-18 1993-07-14 Fuji Yakuhin Kogyo Kabushiki Kaisha Milieu de culture tissulaire sans serum, contenant un inhibiteur tissulaire de metalloproteinase, et procede de croissance cellulaire
WO1995024921A1 (fr) * 1994-03-16 1995-09-21 Institute Of Ophthalmology Utilisation a des fins medicales d'inhibiteurs de metalloproteases matricielles dans le traitement de la contraction tissulaire

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003785A1 (fr) * 1986-11-20 1988-06-02 Vacanti Joseph P Neomorphogenese chimerique d'organes par implantation cellulaire controlee mettant en oeuvre des matrices artificielles
EP0282746A1 (fr) * 1987-02-19 1988-09-21 Takeda Chemical Industries, Ltd. Procédé de préparation de tissu cultivé de manière artificielle
EP0435362A1 (fr) * 1989-12-04 1991-07-03 The Research Foundation Of State University Of New York Composition contenant un agent non-stéroide anti-inflammatoire et une tétracycline à effet nonantibactérien
EP0550760A1 (fr) * 1991-07-18 1993-07-14 Fuji Yakuhin Kogyo Kabushiki Kaisha Milieu de culture tissulaire sans serum, contenant un inhibiteur tissulaire de metalloproteinase, et procede de croissance cellulaire
WO1995024921A1 (fr) * 1994-03-16 1995-09-21 Institute Of Ophthalmology Utilisation a des fins medicales d'inhibiteurs de metalloproteases matricielles dans le traitement de la contraction tissulaire

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048617A3 (fr) * 1999-02-18 2001-02-08 Univ Manchester Ramollissement des tissus conjonctifs
WO2000048617A2 (fr) * 1999-02-18 2000-08-24 Renovo Limited Ramollissement des tissus conjonctifs
US6455569B1 (en) 1999-02-18 2002-09-24 Renovo Ltd Connective tissue softening
EP2324863A1 (fr) * 2000-03-27 2011-05-25 Shiseido Company, Ltd. Procédé de production de peau artificielle
WO2001072347A1 (fr) * 2000-03-27 2001-10-04 Shiseido Company, Ltd. Agents favorisant la formation d'une membrane de base de la peau, agents favorisant la formation d'une peau artificielle et procede de production de peau artificielle
KR100841667B1 (ko) * 2000-03-27 2008-06-27 가부시키가이샤 시세이도 피부 기저막 형성 촉진제, 인공 피부 형성 촉진제 및 인공피부의 제조 방법
US7645595B2 (en) 2000-03-27 2010-01-12 Shiseido Company, Ltd. Method of production of artificial skin
US7160333B2 (en) 2000-08-04 2007-01-09 Depuy Orthopaedics, Inc. Reinforced small intestinal submucosa
WO2002049593A3 (fr) * 2000-12-20 2002-12-27 Henkel Kgaa Utilisation d'enzymes de reparation de l'adn en tant qu'inhibiteurs de mmp-1
WO2002049593A2 (fr) * 2000-12-20 2002-06-27 Henkel Kommanditgesellschaft Auf Aktien Utilisation d'enzymes de reparation de l'adn en tant qu'inhibiteurs de mmp-1
US7201917B2 (en) 2001-07-16 2007-04-10 Depuy Products, Inc. Porous delivery scaffold and method
US7163563B2 (en) 2001-07-16 2007-01-16 Depuy Products, Inc. Unitary surgical device and method
US7361195B2 (en) 2001-07-16 2008-04-22 Depuy Products, Inc. Cartilage repair apparatus and method
US7927606B2 (en) 2003-02-06 2011-04-19 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7569233B2 (en) 2004-05-04 2009-08-04 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
US8864844B2 (en) 2004-05-11 2014-10-21 Synthasome, Inc. Tissue scaffold
US7354627B2 (en) 2004-12-22 2008-04-08 Depuy Products, Inc. Method for organizing the assembly of collagen fibers and compositions formed therefrom
US7595062B2 (en) 2005-07-28 2009-09-29 Depuy Products, Inc. Joint resurfacing orthopaedic implant and associated method
EP2543396A1 (fr) * 2010-03-04 2013-01-09 Shiseido Company, Ltd. Peau artificielle
EP2543396A4 (fr) * 2010-03-04 2013-08-14 Shiseido Co Ltd Peau artificielle
US8871505B2 (en) 2010-03-04 2014-10-28 Shiseido Company, Ltd. Artificial skin
US9579310B2 (en) 2010-03-04 2017-02-28 Shiseido Company, Ltd. Artificial skin
JP2015533505A (ja) * 2012-10-18 2015-11-26 ライフライン サイエンティフィック インコーポレイテッドＬｉｆｅｌｉｎｅ Ｓｃｉｅｎｔｉｆｉｃ， Ｉｎｃ． 生物材料特性の維持および保存方法
US11930809B2 (en) 2012-10-18 2024-03-19 Lifeline Scientific, Inc. Preservation of biomaterial properties and methods of storing

Also Published As

Publication number Publication date
AU8451498A (en) 1999-02-10
GB9714936D0 (en) 1997-09-17

Similar Documents

Publication Publication Date Title
Malda et al. Low oxygen tension stimulates the redifferentiation of dedifferentiated adult human nasal chondrocytes
Malda et al. Expansion of human nasal chondrocytes on macroporous microcarriers enhances redifferentiation
US6465205B2 (en) In vitro cell culture device including cartilage and methods of using the same
Zheng et al. Recurrent inguinal hernia: disease of the collagen matrix?
Kudva et al. Gelatin microspheres releasing transforming growth factor drive in vitro chondrogenesis of human periosteum derived cells in micromass culture
JP3808900B2 (ja) 結合組織細胞に部分的又は完全に分化した骨髄幹細胞の有効培養物及びヒアルロン酸誘導体より成る三次元の生体親和性で且つ生分解性のマトリックスから構成される生物学的物質
Uriel et al. The role of adipose protein derived hydrogels in adipogenesis
JP5620052B2 (ja) 上皮細胞の分離方法、細胞を前条件付けする方法、およびバイオ人工皮膚もしくは真皮を上皮細胞または条件付けされた細胞を用いて調製する方法
AU2009212946B2 (en) Autologous cells on a support matrix for tissue repair
Adkisson IV et al. In vitro generation of scaffold independent neocartilage
Dangaria et al. Extracellular matrix-mediated differentiation of periodontal progenitor cells
CN101203601B (zh) 用于组织填充的分化的未成熟脂肪细胞和生物可降解支架的移植
Brown et al. Bladder acellular matrix as a substrate for studying in vitro bladder smooth muscle–urothelial cell interactions
Chung et al. Bioadhesive hydrogel microenvironments to modulate epithelial morphogenesis
WO1999003979A1 (fr) Methodes de preparation d'un tissu cellulaire artificiel
US20090297579A1 (en) Control of Cells and Cell Multipotentiality in Three Dimensional Matrices
Hofmann et al. Bioengineered human bone tissue using autogenous osteoblasts cultured on different biomatrices
US7189567B2 (en) Method of culturing human chondrocytes
Gu et al. Chondrogenesis of myoblasts in biodegradable poly-lactide-co-glycolide scaffolds
JP2006514562A (ja) 試験管内で生産された三次元組織を組織細胞及び／又は外因性因子と組合わせて用いた罹患組織、変性組織又は損傷組織の治療方法
Bilic et al. Human preterm amnion cells cultured in 3-dimensional collagen I and fibrin matrices for tissue engineering purposes
Wilshaw et al. Investigation of the antiadhesive properties of human mesothelial cells cultured in vitro on implantable surgical materials
JP2003169846A (ja) 基底膜標品等を用いた再構築人工組織及びその製造方法
US8637065B2 (en) Dermis-derived cells for tissue engineering applications
CN113476371B (zh) 一种能提升透明质酸分泌与胶原蛋白合成的组合物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载